Preferred Label : Pan-KRAS Inhibitor BGB-53038;
NCIt synonyms : KRAS Mutant-selective Inhibitor BGB-53038; Pan-KRAS Mutant Inhibitor BGB-53038; KRAS Inhibitor BGB-53038;
NCIt definition : An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic
activity. Upon oral administration, pan-KRAS inhibitor BGB-53038 selectively targets,
binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent
signaling. This inhibits the proliferation of and induces apoptosis in tumor cells
in which KRAS is mutated. KRAS, a member of the RAS family of oncogenes, plays an
important role in cell signaling, division and differentiation. Mutations of KRAS
may induce constitutive signal transduction leading to tumor cell growth, proliferation,
invasion, and metastasis. BGB-53038 has only weak inhibitory activity against NRAS
and HRAS, which may reduce the risk of side effects.;
Molecule name : BGB-53038; BGB 53038;
Origin ID : C215026;
concept_is_in_subset
- has_target
